MedTrace Logo

Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS)

NCT01250847 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2011-08-19

No results posted yet for this study

Summary

The primary objective of this study is to assess the effects of 'Seroquel-XR' on the verbal learning ability in people with at-risk mental state (ARMS) over a 12 week period. The verbal learning ability will be indexed by delayed free recall score of CVLT(California Verbal learning Test), a standard neuropsychological verbal memory tests.

The secondary objective is to assess the effects of 'Seroquel-XR' on other cognitive function and psychiatric symptoms including psychotic, anhedonic symptoms, and impulsivity. The cognitive function abilities will be measured by standard neuropsychological tests as follows;

* Working memory: verbal \& spatial 2-back test
* Attention: Digit Span, 3-7 CPT(Continuous Performance Test)
* Executive function: WCST (Wisconsin Card Sorting Test)
* Visuo-spatial ability: Rey Complex Figure Task copy
* Visuomotor speed and planning: Trail making test A \& B
* Verbal fluency: Controlled Oral Word Association Test(COWAT) The scales of psychiatric symptoms which will be used are as follows;
* Psychotic symptoms: Scales of Prodromal scales (SOPS), Positive and negative syndrome scale (PANSS)
* Anhedonia: Social Anhedonia Scale (SAS), Physical Anhedonia Scale (PAS)
* Social cognition: Ambiguous Intention Hostility Questionnaire (AIHQ)
* Impulsivity: Barrett Impulsivity Scale (BIS)

Conditions

Interventions

DRUG

Quetiapine(Seroquel-XR) 50~800mg a day

The only ARMS subjects will be given 50\~800mg Seroquel-XR once daily for total of 12 weeks.

Sponsors & Collaborators

  • Severance Hospital

    lead OTHER

Principal Investigators

  • Suk Kyoon An, MD, Ph D · Severance Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-10-31
Completion
2012-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01250847 on ClinicalTrials.gov